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ABSTRACT
Background Adalimumab blocks the action of tumor 
necrosis factor-α and reduces disease progression in 
rheumatoid arthritis and psoriatic arthritis. The effects 
of adalimumab in controlling progression of structural 
damage in erosive hand osteoarthritis (HOA) were 
assessed. 
Methods Sixty patients with erosive HOA on radiology 
received 40 mg adalimumab or placebo subcutaneously 
every two weeks during a 12-month randomized double-
blind trial. Response was defi ned as the reduction in 
progression of structural damage according to the 
categorical anatomic phase scoring system. Furthermore, 
subchondral bone, bone plate erosion, and joint-space 
narrowing were scored according to the continuous 
Ghent University Score System (GUSSTM). 
Results The disease appeared to be active since 
40.0% and 26,7% of patients out of the placebo and 
adalimumab group, respectively, showed at least one 
new interphalangeal (IP) joint that became erosive during 
the 12 months follow-up. These differences were not 
signifi cant and the overall results showed no effect of 
adalimumab.
Risk factors for progression were then identifi ed and the 
presence of palpable soft tissue swelling at baseline 
was recognized as the strongest predictor for erosive 
progression. In this subpopulation at risk, statistically 
signifi cant less erosive evolution on the radiological 
image (3.7%) was seen in the adalimumab treated 
group compared to the placebo group (14.5%) (P = 
0.009). GUSSTM scoring confi rmed a less rapid rate of 
mean increase in the erosion scores during the fi rst 6 
months of treatment in patients in adalimumab-treated 
patients.
Conclusion Palpable soft tissue swelling in IP joints in 
patients with erosive HOA is a strong predictor for erosive 
progression. In these joints adalimumab signifi cantly 
halted the progression of joint damage compared to 
placebo.
Moderate to severe hand osteoarthritis is estimated 
to occur in 5–8% Caucasian adults above the age 
of 60 years.1 2 Similar data have been reported in 
the USA.3 In this population, marked destructive 
changes4–7 occur mostly in the distal and proximal 
interphalangeal joints, which eventually result in 
considerable disability.8 9
As there is still lack of agreement concerning the 
nature and speciﬁ city of erosive osteoarthritis as a 
distinct subset of hand osteoarthritis, clear epide-
miological data are scarce. In a survey on the entire 
health district in the Venetian area, radiographic 
erosive osteoarthritis of the interphalangeal joints 
occurred in 8.5% of subjects above the age of 40 
years.10 These ﬁ gures were conﬁ rmed in two large 
population studies in which the prevalence of 
radiographic erosive interphalangeal osteoarthritis 
in subjects over 55 years of age ranged between 
5.0% and 9.9%.11 12
The changes in both the joint space and sub-
chondral bone that characterise the erosive phase 
of the interphalangeal ﬁ nger joints strongly sug-
gest the involvement of pro-inﬂ ammatory cytokine 
cascades known to cause cartilage degradation and 
bone resorption. Among these, tumour necrosis rac-
tor alpha (TNFα) directly stimulates osteoclast pro-
genitors of the monocyte/macrophage lineage into 
osteoclasts, enhances the production of a series of 
proinﬂ ammatory cytokines, eg, interleukin-1 (IL-1), 
receptor activator for nuclear factor κ B ligand, and 
increases the rate of tissue remodelling by matrix-
degrading proteases.13–15
 Adalimumab (Humira; Abbott Laboratories, 
Abbott Park, Illinois) is a bioengineered fully 
human monoclonal antibody that binds to 
TNFα, preventing it from activating TNFα recep-
tors.16 In rheumatoid arthritis (RA), adalimumab 
slowed down progressive joint destruction.17–19 
The authors evaluated the efﬁ cacy and safety 
of adalimumab, 40 mg subcutaneous adminis-
tration, every 2 weeks, to control the structural 
damage to cartilage and bone, as determined by 
radiographic assessment, in erosive osteoarthri-
tis of the interphalangeal ﬁ nger joints in a double 
blind, placebo controlled randomised clinical trial 
of 1 year.
PATIENTS AND METHODS
Patient inclusion/exclusion criteria
Sixty patients were recruited from the out-
patient rheumatology clinic of the Ghent 
University Hospital between May 2006 and 
January 2008. Patients were eligible for study if: 
(1) they were 18 years or older; (2) had hand 
osteoarthritis (meeting the American College 
of Rheumatology criteria)20 characterised by 
painful, inflammatory episodes of the interpha-
langeal joints; (3) presented with at least one 
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Expected intergroup difference and sample size calculation
The sample size was calculated based on the results from pre-
vious studies7 21 22 and is applicable for the evolution between 
baseline and 1 year. The number of patients required for this 
study was 20 in both treatment arms. It can be estimated that 
after 1 year, 60% of patients in the placebo group and 10% of 
patients in the adalimumab group will have started the erosive 
phase in their ‘S’ or ‘J’ joints. Taking into account 20 patients 
in each subgroup, a power of 80% and an α-level of 5%, the 
present study should be able to detect a signiﬁ cant difference 
between the placebo and treatment groups when 50–55% of the 
treated patients have started the erosive phase in one or more 
non-erosive interphalangeal joints. Considering a drop-out rate 
comparable with the previous studies22 a total of 60 patients 
were included.
Randomisation and treatment
Patients received 40 mg adalimumab or placebo administered 
subcutaneously every 2 weeks for 52 weeks. Randomisation of 
the study medication was done in by the subsidising company 
and successive treatment allocation numbers were administered 
by the investigators following the order of inclusion.
Stable doses of analgesics and anti-inﬂ ammatory drugs were 
allowed as adjuvant therapy. In the case of latent tuberculosis or 
the presence of other risk factors for activation of latent tubercu-
losis, the patient was treated with tuberculostatic therapy (iso-
niazid treatment) at least 3 months before initiation of the trial 
and continued up to 9 months.
Outcomes
Primary endpoints were the control of structural damage on 
radiography. Therefore, posteroanterior radiographs of the 
interphalangeal finger joint in the ‘E’ phase as defined by 
Verbruggen and Veys7 on radiography; and (4) were willing 
to self-administer subcutaneous injections or allow a suit-
able person to perform this.
Patients were excluded from the study if they had received 
previous treatment with any investigational agent within 30 
days (or ﬁ ve half lives of the product when longer). Previous 
treatment with chondroitin sulfate, glucosamine, avocado-
soybean unsaponiﬁ ables, tetracyclines, corticosteroids or any 
immunomodulating drug with possible effects on pro-inﬂ am-
matory cytokine metabolism within 90 days was another 
reason for exclusion. Patients with chronic inﬂ ammatory rheu-
matic disease (eg, RA, spondylarthropathy, psoriatic arthritis, 
gout, chondrocalcinosis or other autoimmune diseases) were 
excluded as well as underlying comorbidities, eg, uncon-
trolled diabetes, unstable ischaemic heart disease, congestive 
heart failure, active inﬂ ammatory bowel disease, recent stroke 
(within 3 months before screening), chronic leg ulcer, lymphop-
roliferative disorders, history of cancer, active hepatitis B or C 
infection, positive HIV status and persistent or recurrent infec-
tions requiring treatment with antibiotics within 30 days before 
enrolment.
Levels of rheumatoid factor, anti-citrullinated cyclic pep-
tide, erythrocyte sedimentation rate and C-reactive protein 
were measured at screening. Screening for tuberculosis was 
done by puriﬁ ed protein derivate skin test and x-ray of the 
chest.
This investigator-initiated study was declared at www.
ClinicalTrials.gov (EudraCT number 2006-000925-71) and com-
plied with the principles of the Declaration of Helsinki. The 
study protocol was approved by the Ghent University Hospital 
Ethics Committee. All patients provided written informed 
consent.
Figure 1 Clinical appearance of erosive osteoarthritis of the interphalangeal fi nger joints is illustrated in (A) where erosive progression and 
subsequent remodelling caused functional inability of the second, third and fi fth digit, and in (B) where almost all interphalangeal joints of both hands 
were affected and disabled. Remodelling of the interphalangeal joints in (B) after the erosive process is shown on the corresponding radiograph (C). 
Typically, metacarpophalangeal joints are spared in this condition. (D and E) Erosive progression and subsequent remodelling in two different proximal 
interphalangeal (PIP) joints is shown in a series of radiographic images taken at 6-month intervals. PIP joints in which the synovial joint space has 
disappeared (‘J’ phase) pass through the erosive’E’ phase and eventually remodel (‘R’).
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space on a 11-point rating scale (range 0–100 with intervals of 10 
units). The three scores were summed to obtain the total GUSS 
score that ranged from 0 (severe joint destruction) to 300 (no 
damage) for each interphalangeal ﬁ nger joint. ‘E’ phase interpha-
langeal joints thus have, on average, lower GUSS scores than ‘J’ 
or ‘R’ joints.
Two readers (RW, GV) scored the ﬁ lms independently 
blinded for order, treatment assignment and clinical response. 
Interreader and intrareader intraclass coefﬁ cients of correla-
tion scores rated excellent for the total GUSS scores: 0.86 and 
0.97, respectively. The smallest detectable change,24 as calcu-
lated on the mean scores of the two readers was reduced to 18 
units after training during routine in-house training sessions. 
The mean scores of the two readers were used for the GUSS 
readings.
Secondary endpoints consisted of effects on clinical variables. 
Clinical assessment was performed by the same experienced 
examiner, blinded for treatment assignment, at screening, base-
line and after 6, 12, 26, 39 and 52 weeks. This included the eval-
uation of pain on palpation and the search for palpable swelling 
as a result of synovial thickening and intra-articular effusion25 in 
16 interphalangeal ﬁ nger joints. The grip strength of both hands 
was measured using a hand grip dynamometer (My-Gripper; 
Yamasa, Tokei, Japan). The maximum of three attempts was 
recorded for the dominant and non-dominant hand. Level 
of pain, morning stiffness and function was registered by the 
self-reported AUSCAN questionnaire.26 The occurrence of any 
adverse events was questioned at every visit. Blood samples 
were obtained at baseline and at 6 and 12 months for routine 
safety tests.
hands were obtained at baseline and after 26 and 52 weeks. All 
interphalangeal joints (distal interphalangeal 2–5 and proximal 
interphalangeal 2–5) of both hands were scored except the inter-
phalangeal joints of the thumb because of decreased visibility 
and reproducibility to evaluate on posteroanterior views. A total 
of 960 interphalangeal joints was scored. In order to score the 
erosive progression of the interphalangeal joints on the radio-
graphs, two validated scoring systems were used as co-primary 
endpoints. The ﬁ rst scoring system was based on the consecu-
tive anatomical phases recognised during progressive disease in 
erosive hand osteoarthritis.7 Non-erosive osteoarthritis joints 
(‘S’ or stationary osteoarthritis) have been shown to enter the 
‘J’ phase when the joint space disappears, followed by the ‘E’ 
phase when manifest erosive changes occur. Next, the affected 
interphalangeal joint show signs of repair and the ‘R’ (remodel-
ling) phase ensues. A fusion (‘F’), as an extreme form of joint 
remodelling, is seen extremely rarely. Characteristic features and 
changes are illustrated in ﬁ gure 1. Anatomical phases of all inter-
phalangeal joints were characterised and changes in phase were 
recorded by two readers. The percentage of absolute agreement 
between the readers was 93.6% (κ=0.92). Both readers showed 
intrareader reliabilities with a percentage of absolute agree-
ment of over 95.9% (κ=0.95). In case of dispute, agreement was 
sought by discussing the radiographs. The primary endpoint was 
a reduction in the numbers of ‘N’, ‘S’ or ‘J’ joints that become ‘E’ 
within 1 year at the joint and at the patient level.
The second scoring system was the quantitative Ghent 
University score system (GUSS).23 Erosive progression and signs 
of repair or remodelling were scored by indicating the propor-
tion of normal subchondral bone, subchondral plate and joint 
Table 1 Baseline demographic, clinical and radiology data (N=60)
 
Adalimumab 
(N=30)
Placebo 
(N=30) p Value
Demographics
Women (%) 86.7 83.3 0.704
BMI (kg/m2) ±SD 24.8±3.6 26.5±4.4 0.122
Age at baseline (years) ±SD 61.9±6.1 60.7±6.9 0.769
Disease duration (years) ±SD 9.6±6.1 14.4±8.8 0.016
Clinical data
AUSCAN pain ±SD 20.4±9.0 25.1±11.1 0.008
AUSCAN stiffness ±SD 5.1±2.3 5.5±2.6 0.322
AUSCAN function ±SD 48.4±20.2 54.1±21.0 0.006
No of tender joints* ±SD 3.3±2.7 5.0±3.7 0.014
No of palpable effusions* ±SD 3.2±3.0 2.5±2.5 0.201
Maximal grip strength
Dominant hand (kg) ±SD 18.4±9.6 19.4±10.1 0.398
Non-dominant hand (kg) ±SD 17.2±7.4 18.3±9.4 0.258
Analgesics and NSAID intake (N) (%) 9.0 (30.0%) 8.0 (26.7%) 0.104
Radiological data
Phases at baseline† (N=960)
‘N’/’S’ (%) (N) 81.7% (392/480) 83.3% (400/480) 0.201
‘J’ (%) (N) 5.6% (27/480) 6.0% (29/480) 0.658
‘E’ (%) (N) 7.7% (37/480) 6.4% (31/480) 0.456
‘R’ (%) (N) 5.0% (24/480) 4.0% (19/480) 0.587
‘F’ (%) (N) 0.0% (0/480) 0.2% (1/480) 0.920
Thumb base osteoarthritis‡
None (N) 6 7 0.902
Mild (N) 13 11 0.811
Moderate/severe (N)  11 12 0.935
*Sixteen joints were assessed (proximal interphalangeal 2–5 and distal interphalangeal 2–5 of both hands; interphalangeal P1 is 
excluded).
†Nine-hundred and sixty joints were assessed in 60 patients.
‡Thumb base osteoarthritis: none: if absent in both hands; mild–moderate/severe: if present in at least one hand; ‘E’ erosive; ‘F’ fusion; 
‘J’ joint space loss; ‘N’ normal; ‘R’ remodelled; ‘S’ stationary non-erosive osteoarthritis.
Except where indicated otherwise, data shown are mean values; AUSCAN data scales: pain 0–50; stiffness: 0–10; function: 0–90.
BMI, body mass index; NSAID, non-steroidal anti-infl ammatory drug.
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modelling, no imputation was used. All statistics were calcu-
lated using SPSS 16.
RESULTS
Patient characteristics
Sixty patients were enrolled in the study. Both adalimumab 
and placebo-treated groups included 30 subjects. None of the 
patients were rheumatoid factor or anti-citrullinated cyclic pep-
tide positive. Six patients, of which four were in the adalimumab 
group, showed positive puriﬁ ed protein derivate skin tests with 
no signs of active pulmonary tuberculosis. Here, izoniazid treat-
ment was initiated. Demographic characteristics between both 
treatment groups were compared (table 1). A ﬂ ow diagram of 
the study is provided in ﬁ gure 2.
Structural changes in interphalangeal joints: 
overall treatment effects
Anatomical phases and changes over time of all 960 interphalan-
geal joints were characterised.
At baseline, 68 out of 960 (7.1%) interphalangeal ﬁ nger joints 
were in the ‘E’ phase, 43 (4.5%) in the ‘R’ phase and one joint 
was fused. Of the remaining 848 (88.3%) interphalangeal ﬁ nger 
joints in the ‘N’, ‘S’ or ‘J’ phases at baseline, 24 (2.8%) from 20 
patients became fully erosive interphalangeal joints after 1 year.
Fifteen out of 429 (3.6%) ‘N’, ‘S’ or ‘J’ joints from placebo-
treated patients showed an evolution to an ‘E’ joint compared 
with nine of 419 (2.1%) joints in adalimumab-treated patients 
(GEE OR 1.43; 95% CI 0.65 to 3.16, p=0.37). Active disease, 
deﬁ ned by the presence of at least one new erosive joint over 12 
months, was present in 12 of 30 (40.0%) and eight of 30 (26.7%) 
Statistical analysis
Descriptive analyses were performed by the calculation of 
means, mean differences and proportions. t Tests and χ2 tests 
were used to explore differences between groups for continuous 
and dichotomous variables, respectively. For the evaluation of 
joints, the classic methods neglect the fact that treatment is given 
on a patient level. Therefore, additional generalised estimating 
equation (GEE) modelling with a logit link function was used 
to calculate OR and differences of means. An additional level 
(time) was added to the GEE models for longitudinal analysis.
A multi-step method was used to evaluate subgroups of 
patients that might beneﬁ t from anti-TNFα therapy: (1) poten-
tial predictors of erosive progression were evaluated by univari-
ate analysis; (2) variables that showed a 50% difference in odds 
(OR >1.5 or OR <0.667) were added in one multivariate GEE 
model; (3) signiﬁ cant predictors from that model were evalu-
ated by interaction terms with therapy (placebo or adalimumab) 
in further regression analyses. For these subgroup analyses, dis-
ease progression was assessed using the anatomical phase scor-
ing system7 and the GUSS23 as follows: for the evaluation of 
classic calculated OR, a new erosive joint was deﬁ ned if a joint 
with a baseline ‘N’, ‘S’ or ‘J’ phase evolved to an ‘E’ phase after 
1 year. In the GEE models, ‘E’ joints were compared with all 
other phases at the two different time points. For the evaluation 
of the GUSS, differences between baseline were calculated and 
the different scores of these joints showing no evolution were 
imputed with zero.
Concerning the descriptive analyses and the analysis of dif-
ferences, the last observation carried forward method was 
used in the case of missing values (one patient (placebo) missed 
the 12-month visit). For the calculation of inference by GEE 
Figure 2 Flow diagram of the study. GEE, general estimating equation; LOCF, last observation carried forward; SC, subcutaneous.
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factor and revealed a signiﬁ cant interaction term for palpable 
effusion with therapy.
Adalimumab treatment prevents erosive evolution in patients 
with soft tissue swelling at baseline: nine of these inﬂ amed 
interphalangeal joints out of 62 (14.5%) at baseline became 
erosive under placebo treatment versus three out of 81 (3.7%) 
under adalimumab therapy (GEE OR 4.57; 95% CI 1.46 to 14.3, 
p=0.009; ﬁ gure 3A). Similarly, treatment with adalimumab 
causes a fourfold reduction in the risk of erosive progression 
compared with placebo.
In addition, we evaluated whether the differences between 
groups, observed with the anatomical phase scoring method, 
could be conﬁ rmed by GUSS.
Joints showing baseline palpable swelling from patients 
treated with placebo showed signiﬁ cantly more change of GUSS 
scores towards progression between baseline and 6 months than 
patients in the placebo and adalimumab-treated groups, respec-
tively (p=0.09). The differences were not signiﬁ cant.
Structural changes in interphalangeal joints: 
predictors for erosive evolution
From the demographic data, three variables were recognised as 
potential predictors for erosive evolution: disease duration, the 
number of tender joints at baseline and the number of joints 
with palpable effusion at baseline. The latter variable was asso-
ciated with the highest risk of erosive evolution (table 2).
Treatment effects on interphalangeal fi nger 
joints at risk of erosive evolution
GEE modelling (with a logit link function) was used to explore 
the interaction terms between treatment and each selected risk 
Figure 3 (A) Effect of adalimumab in interphalangeal fi nger joints at high risk of erosive disease. Tenfold increase in percentage numbers of 
interphalangeal fi nger joints that progress to erosive disease, as observed in joints showing palpable effusion at baseline, are signifi cantly reduced in 
the treatment group. (B) Ghent University score system (GUSS) scores in interphalangeal fi nger joints. Differences in GUSS scores between baseline 
(normalised), 6 and 12 months in interphalangeal joints with and without palpable effusion in treatment and placebo groups. Mean values and SEM 
are given. P, Non-swollen interphalangeal—placebo; A, non-swollen interphalangeal—adalimumab; sw-P, swollen interphalangeal—placebo; 
sw-A, swollen interphalangeal—adalimumab.
Table 2 Exploration of potential risk factors for more erosive disease
Continuous variables Mean difference (SE)† GEE OR (95% CI) p Value‡
Disease duration +4.20 (1.60) 0.95 (0.91 to 0.98) 0.014
Age +1.90 (1.80) 1.01 (0.96 to 1.08) 0.560
Baseline CRP −0.02 (0.05) 0.99 (0.95 to 1.05) 0.970
Baseline ESR +1.98 (2.10) 1.00 (0.99 to 1.00) 0.440
Dichotomous variables OR* (95% CI) GEE OR (95% CI) p Value‡
Tender joints at baseline (N) 3.30 (1.40 to 7.60) 2.50 (1.10 to 5.70) 0.030
Palpable effusion at baseline 5.30 (2.30 to 12.0) 4.40 (2.10 to 8.80) 0.001
PIP joint vs DIP joint 1.50 (0.60 to 3.20) 0.12 (0.78 to 1.03) 0.790
*OR and 95% CI obtained by GEE modelling (multivariate analysis).
†For each item, the mean difference between groups with erosive and non-erosive disease were calculated (univariate analysis).
‡p Values calculated by GEE modelling.
CRP, C-reactive protein; DIP, distal interphalangeal; ESR, erythrocyte sedimentation rate; GEE OR, generalised estimating equation odds 
ratio; PIP, proximal interphalangeal; SE, standard error of mean difference.
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disease in order to prevent the progression of structural remod-
elling. The destructive events, ie, the osteolytic processes and 
the disappearance of the articular cartilage in osteoarthritis, are 
most likely mediated by the same cytokine cascades opera-
tional in other inﬂ ammatory rheumatic conditions, eg, RA and 
psoriatic arthritis.31–35 Here in states of skeletal inﬂ ammation 
TNFα is produced, which is the dominant cytokine present in 
inﬂ ammation-associated joint tissue destruction. TNFα directly 
stimulates osteoclast progenitors of the monocyte/macrophage 
lineage to differentiate to osteoclasts,13 14 and augments receptor 
activator for nuclear factor κ B ligand expression,14 IL-1 and its 
signalling receptor IL-1R1 messenger RNA 14 15 in bone marrow 
stromal cells and synovial ﬁ broblasts. It is likely that TNFα activ-
ity may be responsible for the destructive processes observed in 
cartilage and subchondral bone in erosive interphalangeal joint 
osteoarthritis.
TNFα blockade is thus a possible therapeutic option in ero-
sive interphalangeal joint osteoarthritis as it could help to pre-
serve tissue structure and hand function as a whole.
For this study we selected patients showing active erosive 
osteoarthritis in one or more of their interphalangeal ﬁ nger 
joints. The natural history in these patients showed high rates 
of progression, as almost half of them on placebo had one or 
more non-erosive interphalangeal joints at baseline that became 
erosive during follow-up.
Fewer adalimumab-treated patients developed erosive 
osteoarthritis in their interphalangeal joints: 26.7% of patients 
in 2.1% of their non-erosive interphalangeal joints, whereas 
40.0% of the placebo-treated patients did so in 3.6% of their 
non-erosive ﬁ nger joints. These differences were not signiﬁ cant 
and the overall results thus showed no therapeutic effect of 
adalimumab.
However, the data obtained in the placebo group allowed 
potential predictors for erosive evolution in interphalangeal ﬁ n-
ger joint osteoarthritis to be identiﬁ ed. Most signiﬁ cantly, soft 
tissue swelling at study entry was a key predictor for erosive 
evolution. In the placebo group, a 10-fold increase in progres-
sion to the erosive ‘E’ phase occurred in non-erosive interpha-
langeal joints presenting with soft tissue swelling. Neutralising 
TNFα signiﬁ cantly slowed down the progression of structural 
damage in these inﬂ amed interphalangeal joints.
These results were conﬁ rmed when erosive progression in this 
particular form of hand osteoarthritis was scored by the novel 
scoring system GUSS, designed to monitor disease progression 
within a shorter time. Anti-TNFα therapy prevented GUSS from 
changing in interphalangeal joints with palpable effusion at base-
line. In the placebo group, GUSS scores dropped dramatically in 
from patients treated with adalimumab (mean difference −20.0, 
SE 9.9, p=0.022; GEE model; ﬁ gure 3B). These interphalangeal 
joints started to repair and remodel during further follow-up 
(ﬁ gure 1D,E). Renewal of the tissue structures then resulted in 
higher GUSS scores after 12 months. GUSS scores remained 
stable under adalimumab in joints showing baseline palpable 
swelling. Non-swollen interphalangeal joints did not show any 
change in their GUSS scores.
Clinical variables
Differences in clinical variables between baseline and week 
52 are shown in table 3. No signiﬁ cant changes were observed 
between both treatment groups after 1 year (table 4).
DISCUSSION
Erosive hand osteoarthritis targets interphalangeal joints and 
shows severe radiographic subchondral bone destruction and car-
tilage attrition with poor long-term functional outcome,8 9 27–29 
and functional impairment caused by hand osteoarthritis was 
reported to be similar in severity to that in RA.30 Meaningful 
treatment should deal with the destructive events during the 
Table 3 Longitudinal clinical data
Variable Adalimumab (N=30) Placebo (N=30) p Value
AUSCAN pain 5.4 (9.8) 1.7 (13.1) 0.063
AUSCAN stiffness 0.4 (2.1) 0.1 (3.0) 0.721
AUSCAN function 1.2 (18.5) 2.0 (17.9) 0.133
No of tender joints 0.7 (2.3) 1.4 (4.8) 0.238
No of joints with palpable effusion
Maximal grip strength (kg) 1.7 (2.7) 1.0 (2.4) 0.814
Dominant hand 0.8 (1.2) 1.2 (1.8) 0.231
Maximal grip strength
Non-dominant hand 0.9 (1.3) 0.2 (1.1) 0.281
Data shown are mean differences (SD) in changes of scores from baseline to week 52.
Safety results are reported in table 4. More adverse events were reported in the adalimumab group (N=13) than in the placebo group 
(N=8), although more infectious adverse events were seen in the placebo group (four vs only two in the adalimumab group). Three 
infections required antibiotics. All adverse events were graded as mild to moderate in severity and only one case required withdrawal 
from the study. This patient withdrew consent after experiencing vertigo and hypertension 9 months after baseline. This patient was 
treated with placebo. No serious adverse events or malignancies occurred. Biological routine safety blood tests revealed no problems.
Table 4 Adverse events
 Placebo (N=30) Adalimumab (N=30)
Adverse events 8 13
Patients experiencing at least one 
adverse event 8
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numbers of adverse events; adverse events marked with * may be treatment related.
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the interphalangeal joints before increasing towards the end of 
the follow-up period as a result of spontaneous repair. 7 It can be 
presumed that remodelling of an affected interphalangeal joint 
after major tissue damage will result in a marked change of the 
original anatomy and loss of the normal function.
Anti-TNF therapy retarded erosive progression in RA and 
psoriatic arthritis,17–19 and clinical improvement was associated 
with the inhibition of TNF activity in most although not in all of 
these studies.17 19 In fact, erosive progression could be halted in 
RA during anti-TNF therapy even though clinical signs of joint 
inﬂ ammation remained.36
Also in our study in hand osteoarthritis, anti-TNF treatment 
did not show any effect on inﬂ ammation, as assessed by the 
number of joints with palpable swelling that remained constant 
throughout follow-up. The direct causal relationship between 
synovitis and bone erosions in RA has been questioned, and ero-
sions and the signs of synovitis may represent different patho-
logical processes.37
Thus far, two open-label studies have reported on the effects 
of TNF inhibition on clinical variables in hand osteoarthritis.38 
39 One underpowered open-label study failed to show any 
clinical effect,38 and it has to be admitted that our study may 
also have been underpowered to perceive clinical change as it 
was powered to detect structure modiﬁ cation. Another single-
blinded study on 10 patients in which 56 and 34 interphalangeal 
joints were injected with inﬂ iximab and placebo, respectively, 
showed a signiﬁ cant reduction of spontaneous pain and pain 
on pressure when individual joints were studied.39 Although 
conclusions are hard to take from open-label studies, it may 
point to a weakness in our study in that we used the AUSCAN, 
which was designed to measure overall hand function. TNFα 
blockade, when retarding disease progression in some selected 
target interphalangeal joints, was not supposed to alter residual 
hand function and pain caused by multiple deformities that 
previously occurred in other ﬁ nger joints. It may be expected, 
however, that treatment interventions given at appropriate 
time intervals will help to preserve tissue structure and hand 
function as a whole over time.
The tolerability and safety proﬁ les of adalimumab in our 
patients with erosive hand osteoarthritis were as good as those 
in patients with other systemic rheumatic diseases.17,40
This placebo controlled randomised clinical trial offers the 
ﬁ rst proof of principle that TNFα neutralisation by adalimumab 
is able to slow down the progression of structural damage in ero-
sive interphalangeal ﬁ nger joint osteoarthritis. This effect was 
only seen in interphalangeal joints with destructive features on 
radiography and with palpable effusion. Larger phase III studies 
should be performed to conﬁ rm these results.
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